Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled rhDNase for atelectasis in mechanically ventilated children
NL-OMON21415Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dornase alfa in atelectasis (2 arms), sponsored by Erasmus MC. Primary endpoint: Change from baseline in chest radiograph score at 48 hours. Started Oct 2006; status: recruiting.
02
Drugs
dornase alfa
03
Conditions
atelectasis
Beyond the preview
Go deeper on NL-OMON21415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21415.